Galapagos NV (Galapagos) is a clinical-stage biotechnology company that specializes in the discovery and development of small-molecule medicines. The company conducts clinical trials in several areas, including inflammatory indications, cystic fibrosis, fibrosis and osteoarthritis. Its pipeline products include 5101, 5201, 5301 and 3667 for the indications of non-hodgkin’s lymphoma, chronic lymphocytic leukemia, multiple myeloma, systemic lupus erythematosus, dermatomyositis and other rare diseases. Galapagos collaborates with various partners and alliances to accelerate pipeline development. It operates in Belgium, the Netherlands, the US, Switzerland, France, Germany, Finland, Norway, Austria and Ireland, among others. Galapagos is headquartered in Mechelen, Belgium.
Headquarters
Belgium
Address
Generaal De Wittelaan L11 A3, Mechelen, 2800
Website
www.glpg.com
Telephone
32 15 342900
No of Employees
646
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GLPG (AMS)
Revenue (2022)
$310.4M
3.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
197.1%
(2022 vs 2021)
Market Cap*
$1.9B
Net Profit Margin (2022)
XYZ
193.9%
(2022 vs 2021)
* As of and is in US$
Galapagos NV premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Oncology |
| 5101: Non-Hodgkin’s lymphoma (NHL) |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In January, the company and Thermo Fisher Scientific entered into a partnership for the decentralized manufacturing of its point-of-care CAR-T product candidate in San Francisco. |
| 2024 | Contracts/Agreements | In January, the company and BridGene Biosciences entered into a strategic collaboration and licensing agreement to develop and discover new precision medicines against clinically validated oncology targets. |
| 2024 | Contracts/Agreements | In January, the company signed an agreement to sell its Jyseleca (filgotinib) business to Alfasigma S.p.A. |
Competitor Comparison
| Key Parameters | Galapagos NV | Mithra Pharmaceuticals SA | TherapeuticsMD Inc | Oxurion NV | Celyad Oncology SA |
|---|---|---|---|---|---|
| Headquarters | Belgium | Belgium | United States of America | Belgium | Belgium |
| City | Mechelen | Liege | Boca Raton | Leuven (Louvain) | Mont-Saint-Guibert |
| State/Province | - | Liege | Florida | - | - |
| No. of Employees | 646 | 229 | 1 | 27 | 12 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Paul Stoffels | Chairman; Chief Executive Officer | Executive Board | 2022 | - |
| Thad Huston | Chief Financial Officer; Chief Operating Officer | Senior Management | 2023 | - |
| Pierre Raboisson | Head - Small Molecules Discovery | Senior Management | 2022 | - |
| Philippe Alen | Senior Vice President; Head - Business Development | Senior Management | 2022 | - |
| Jason Treese | Head - Quality | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward